Skip to content
AnalysisData

GSK and Pfizer join a 100 million-cell AI data project

Parse and Nomic report partner commitments for Cascade, a planned immune-cell dataset. Prices and delivery dates remain undisclosed.

Blue and yellow surface details of a human T cell against a dark background.
A colorized scanning electron micrograph of a human T cell from a healthy donor, dated May 24, 2010. File image.NIAID/NIH · Public domain

Parse Biosciences and Nomic Bio announced plans on October 29 to produce Cascade, a dataset intended to help drug researchers train AI models to predict immune responses. The project will combine measurements of gene activity in 100 million individual cells with measurements of proteins released by groups of cells into surrounding fluid.

The companies named GSK, Pfizer, Sanofi, Graph Therapeutics and Turbine as foundational partners. Parse reported partner commitments; neither announcement disclosed payments or individual contract terms. Nomic said data generation is underway. Researchers are being offered a data partnership while the companies build the resource.

Cascade gives those prospective buyers a specific research proposition: compare what happens inside an immune cell with the signals it sends to other cells after treatment. That pairing could help scientists choose experiments and test computer predictions about drug responses. The announcements describe intended uses, without reporting a demonstrated improvement in drug development from Cascade itself.

Gene activity and protein signals answer different questions

RNA sequencing measures molecules a cell produces as it uses genetic instructions. Messenger RNA carries instructions that cells use to make proteins. Reading those molecules helps scientists identify which genes are active and how activity changes between cells or conditions. The National Human Genome Research Institute describes the transcriptome as the collection of RNA sequences in a cell. Single-cell measurements preserve differences that an average across many cells can obscure.

Protein measurements add information about what cells produce and release. Gene activity alone cannot fully describe how proteins are made, broken down or secreted. A methods paper by Nomic and academic researchers explains why direct protein measurements are needed alongside RNA data.

Parse will produce the RNA measurements in its GigaLab service laboratory. Nomic will use its Omni 1000 platform to measure more than 1,000 secreted proteins from matched samples. Matching the records by donor, treatment and time should let researchers examine how changes in cellular gene activity relate to later protein signals.

The RNA records describe individual cells; the protein records measure fluid collected from groups of cells in matched samples. Nomic’s earlier blood-cell dataset calls this fluid the supernatant. Protein concentration means an amount measured in a given volume of fluid. It describes the group’s output, without assigning each measured protein to one sequenced cell. One protein profile can therefore match RNA records from many individual cells.

Nomic’s protein measurement method has a published experimental history. Its November 2025 Nature Methods paper reported measuring 191 proteins across 7,392 blood-cell samples, yielding about 1.4 million measurements. Researchers compared responses across six donors using 80 different cytokines, signaling proteins used by immune cells, alongside other stimuli. They measured protein concentrations after 24 hours and compared responses with unstimulated samples from the same donors. The study involved the platform’s developers, and its disclosures identify Nomic employment or ownership interests among several authors.

The cell count measures depth within a defined experiment

Nomic’s Cascade specifications list 12 healthy donors, six female and six male, with measurements at four, eight and 24 hours. The planned design covers at least 14 immune cell types and more than 300 treatment conditions per donor at each timepoint. Those conditions include immune-signaling molecules and drugs, used individually or in combinations.

The 100 million figure counts individual-cell RNA profiles within that design. Nomic separately lists more than 11,500 secretome profiles and 12.2 million protein measurements. A secretome is the collection of proteins released by cells. Each protein profile therefore describes a sample containing cells, rather than every sequenced cell receiving its own protein measurement.

That distinction affects what a buyer can study. Many measured cells can reveal variation among cell types within the sampled donors. The reference begins with healthy donors. Nomic describes disease samples and additional donors as ways to extend Cascade, rather than populations already included in the announced reference. A model intended for a particular disease would need evidence relevant to that setting.

Parse’s access page offers Cascade through a data partnership license, with launch-partner licensing open through December 11 and general-partner licensing afterward. Drugmakers and other researchers are prospective licensees; Parse and Nomic supply the measurements. Public materials do not disclose fees, delivery dates, license duration or how payments would be divided between the suppliers. The access page directs interested organizations to a contact form.

Commercial data will sit alongside resources researchers can already obtain openly. Tahoe-100M’s maintained dataset card describes an atlas of gene activity across 50 cancer cell lines exposed to 1,100 small-molecule treatments. It provides data and metadata downloads under a CC0 dedication. Tahoe studies cancer cells; Cascade adds secreted-protein measurements and timed immune responses.

Another data-generation effort illustrates who can finance an open resource. In January, Tahoe Therapeutics, Arc Institute and Biohub announced a joint program for more than 120 million single-cell data points across 225,000 drug-patient interactions. Each organization committed multiple millions of dollars, according to Arc. The plan provides for initial sharing among the three organizations and eventual public release, rather than an immediate public download.

The suppliers have published measurement totals and a licensing timetable, but the reviewed access pages do not specify delivery file formats, experimental controls included with a release or the schedule for receiving its RNA and protein records.

Predicting a new response remains a separate test

Arc’s 2026 Virtual Cell Challenge tests a problem relevant to such purchases: whether models can predict responses in cellular settings they have never seen treated. Entrants must predict the effects of reducing particular genes’ activity in six cell lines, using measurements of their untreated state. Arc holds back experimental responses to judge the predictions. That task tests transfer to unfamiliar biology rather than reproduction of a model’s training examples.

Nomic proposes a comparable evaluation opportunity within Cascade: researchers could leave some donors or treatments out of model training, then test predictions against those withheld measurements. Following protein responses over time would also let them check whether an early cellular signal predicts a later response. Those are potential experiments enabled by the design; neither supplier reports their outcome yet.

December 11 is the next published access milestone. Before committing, prospective partners still need prices, delivery dates and a clear account of which measurements arrive with each release.

Common questions

Who announced the Cascade data project?

Parse Biosciences and Nomic Bio announced Cascade on October 29 as a planned dataset for immune response research.

Which organizations were named as foundational partners?

Parse and Nomic named GSK, Pfizer, Sanofi, Graph Therapeutics and Turbine as foundational partners.

What does Cascade’s 100 million figure count?

The 100 million figure counts planned RNA profiles of individual cells within Cascade’s announced study design.

What does RNA sequencing help researchers see?

RNA sequencing measures molecules made as cells use genetic instructions, helping researchers see which genes are active.

What does a secretome profile measure in Cascade?

A secretome profile measures proteins released into fluid by a group of cells in a matched sample.

Does each sequenced cell get its own protein measurement?

No. Cascade’s protein measurements describe groups of cells. One protein profile can match RNA records from many individual cells.

How many donors are in the planned reference?

Nomic lists 12 healthy donors, six female and six male, in the initial Cascade reference.

Did Cascade announce that it improved drug development?

No. Parse and Nomic described intended research uses and gave no demonstrated improvement in drug development from Cascade.

How did Parse say researchers could obtain Cascade?

Parse offered access through a data partnership license. Its public materials did not specify fees, duration or delivery dates.

How does Cascade differ from the open Tahoe-100M dataset?

Tahoe-100M measures gene activity in cancer cells. Cascade adds matched secreted-protein measurements and tracks immune responses over time.

Sources

All news
DeepMind scientists Demis Hassabis and John Jumper at a Nobel Prize press conference
Research

Scientists Using AI Report a Growing Backlog of Untested Ideas

Two uniformed pallbearers carry a casket bearing a portrait of Mohsen Fakhrizadeh in front of a tiled arch.
Strategy

‘A Nuclear Bomb Is a Joke.’ Where Is Iran’s Uranium?

Dario Amodei in a navy suit and tie stands beside Sanae Takaichi for an official group photograph.
Technology

Anthropic’s IPO Filing Warns of AI Catastrophe and Uninsured Losses

Have data to license or need a source?

Tell us what your company has or what your team needs.

Talk to SnowRock